TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma

Journal of Clinical Oncology

Volumn 28, Issue 5, 2010, Pages 761-766

  Perrone, Federica ^a   Bossi, Paolo ^a   Cortelazzi, Barbara ^a   Locati, Laura ^a   Quattrone, Pasquale ^a   Pierotti, Marco A ^a   Pilotti, Silvana ^a   Licitra, Lisa ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; MUTANT PROTEIN; PROTEIN P53; ANTINEOPLASTIC AGENT; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MULTICENTER STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BIOPSY; DISEASE FREE SURVIVAL; GENETIC SCREENING; GENETICS; MIDDLE AGED; MORTALITY; MOUTH TUMOR; MUTATION; NUCLEOTIDE SEQUENCE; ORAL SURGERY; PATHOLOGY; PATIENT SELECTION; PREDICTION AND FORECASTING; TIME; TRANSCRIPTION INITIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; FLUOROURACIL; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; NEOADJUVANT THERAPY; ORAL SURGICAL PROCEDURES; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77649207406     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.4170     Document Type: Article

References (37)

1. Posner MR, Hershock DM, Blaajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007
2. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007
3. Hitt R, López-Pousa A, Martínez-Trufero J, et al: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636-8645, 2005
4. Cabelguenne A, Blons H, de Waziers I, et al: p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series. J Clin Oncol 18: 1465-1473, 2000 (Pubitemid 30205392)
5. Sullivan A, Syed N, Gasco M, et al: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23:3328-3337, 2004 (Pubitemid 38669822)
6. Temam S, Flahault A, Périé S, et al: p53 gene status as predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 18:385-394, 2000 (Pubitemid 30056429)
7. Eastman A: Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells 2:275-280, 1990
8. Erber R, Conradt C, Homann N, et al: TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 16:1671-1679, 1998 (Pubitemid 28175048)
9. Cho Y, Gorina S, Jeffrey PD, et al: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265: 346-355, 1994 (Pubitemid 24259959)
10. Poeta ML, Manola J, Goldwasser MA, et al: TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357:2552-2561, 2007 (Pubitemid 350294222)
11. Petitjean A, Mathe E, Kato S, et al: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629, 2007 (Pubitemid 46744292)
12. Kato S, Han SY, Liu W, et al: Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100:8424-8429, 2003 (Pubitemid 36842561)
13. Ruggeri EM, Carlini P, Pollera CF, et al: Longterm survival in locally advanced oral cavity cancer: An analysis of patients treated with neoadjuvant cisplatin-based chemotherapy followed by surgery. Head Neck 27:452-458, 2005 (Pubitemid 40770813)
14. Licitra L, Grandi C, Guzzo M, et al: Primary chemotherapy in resectable oral cavity squamous cell cancer: A randomized controlled trial. J Clin Oncol 21:327-333, 2003 (Pubitemid 46606163)
15. Perrone F, Oggionni M, Birindelli S, et al: TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. Int J Cancer 105:196-203, 2003 (Pubitemid 36505321)
16. Licitra L, Perrone F, Bossi P, et al: High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5623-5625, 2006
17. Petitjean A, Achatz MI, Borresen-Dale AL, et al: TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157-2165, 2007
18. Fouret P, Temam S, Charlotte F, et al: Tumor stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumor response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. Br J Cancer 87:1390-1395, 2002
19. Ferlini C, Raspaglio G, Mozzetti S, et al: Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 64:51-58, 2003 (Pubitemid 36759817)
20. Ziółkowska-Seta I, Madry R, Kraszewska E, et al: TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecol Oncol 112:179-184, 2009
21. Strobel T, Swanson L, Korsmeyer S, et al: BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A 93:14094-14099, 1996 (Pubitemid 26424251)
22. McGrogan BT, Gilmartin B, Carney DN, et al: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785:96-132, 2008
23. Sève P, Mackey J, Isaac S, et al: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001-2007, 2005 (Pubitemid 43056983)
24. Wahl AF, Donaldson KL, Fairchild C, et al: Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72-79, 1996
25. Sakashita F, Osada S, Takemura M, et al: The effect of p53 gene expression on the inhibition of cell proliferation by paclitaxel. Cancer Chemother Pharmacol 62:379-385, 2008
26. Zhang CC, Yang JM, Bash Babula J, et al: DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res 59:3663-3670, 1999
27. Hait WN, Yang JM: The individualization of cancer therapy: The unexpected role of p53. Trans Am Clin Climatol Assoc 117:85-101, 2006
28. Lavarino C, Pilotti S, Oggionni M, et al: p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18:3936-3945, 2000
29. Kupryjanczyk J, Kraszewska E, Ziolkowska-Seta I, et al: TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study. BMC Cancer 8:27, 2008
30. Smith-Sørensen B, Kaern J, Holm R, et al: Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 78:375-381, 1998
31. Itamochi H, Kigawa J, Terakawa N: Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 99:653-658, 2008
32. Eastman A: Mechanisms of resistance to cisplatin. Cancer Treat Res 57:233-249, 1991
33. Schmitt CA: Cellular senescence and cancer treatment. Biochim Biophys Acta 1775:5-20, 2007
34. Papazoglu C, Mills AA: p53: At the crossroad between cancer and ageing. J Pathol 211:124-133, 2007
35. Bertheau P, Espié M, Turpin E, et al: TP53 status and response to chemotherapy in breast cancer. Pathobiology 75:132-139, 2008 (Pubitemid 351820731)
36. Perrone F, Suardi S, Pastore E, et al: Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 12:6643-6651, 2006
37. Weinberger PM, Yu Z, Haffty BG, et al: Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 10:5684-5691, 2004